首页 | 本学科首页   官方微博 | 高级检索  
     


Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome
Authors:Andres Chang  Danielle Schlafer  Christopher R. Flowers
Affiliation:1. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA;2. Emory Vaccine Center, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA;3. Department of Pharmaceutical Services, Emory Healthcare, Atlanta, GA, USA
Abstract:Introduction: Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies.

Areas covered: We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgkin lymphomas, and potential predictors of response.

Expert opinion: We anticipate that in the next 10 years, agents that modulate the immune system such as PD-1 antagonists will be increasingly used in favor over traditional cytotoxic chemotherapeutic agents. PD-1 antagonists will be combined with future immunotherapies or used as adjuncts to cellular therapy to boost tumor-specific immune responses.

Keywords:PD-1  PD-L1  non-Hodgkin lymphoma  Hodgkin lymphoma  immunotherapy  PD-1 inhibitor
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号